Literature DB >> 15502066

Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding.

Patrick Wettstein1, André Haeberli, Monika Stutz, Miriam Rohner, Cinzia Corbetta, Konrad Gabi, Thomas Schnider, Wolfgang Korte.   

Abstract

To explore relevant changes in unexplained intraoperative bleeding, we evaluated elements of the final steps of the coagulation cascade in 226 consecutive patients undergoing elective surgery. Patients were stratified for the occurrence of unexplained intraoperative bleeding according to predefined criteria. Twenty patients (8.8%) developed unexplained bleeding. The median intraoperative blood loss was 1350 mL (bleeders) and 400 mL (nonbleeders) (P < 0.001). Fibrinogen and Factor XIII (F. XIII) were more rapidly consumed in bleeders (P < 0.001). Soluble fibrin formation (fibrin monomer) was increased in bleeders throughout surgery (P < or = 0.014). However, F. XIII availability per unit thrombin generated was significantly decreased in bleeders before, during, and after surgery (P < or = 0.051). Computerized thrombelastography showed a parallel, significant reduction in clot firmness. We suggest that mild preexisting coagulopathy is not rare in surgical patients and probably can result in clinically relevant intraoperative bleeding. This hemostatic disorder shows impaired clot firmness, probably secondary to decreased cross-linking (due to a loss of F. XIII, both in absolute measures and per unit thrombin generated). We suggest that the application of F. XIII might be worthwhile to test in a prospective clinical trial to increase clot firmness in patients at risk for this intraoperative coagulopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502066     DOI: 10.1213/01.ANE.0000134800.46276.21

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  15 in total

1.  [Thrombelastometric detection of factor XIII deficiency].

Authors:  C F Weber; C Jambor; M Marquardt; K Görlinger; B Zwissler
Journal:  Anaesthesist       Date:  2008-05       Impact factor: 1.041

Review 2.  [Coagulation management in patients with liver disease].

Authors:  A Bienholz; A Canbay; F H Saner
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-05-05       Impact factor: 0.840

3.  7 Procoagulators.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

4.  Factor XIII Deficiency and Thrombocytopenia Are Frequent Modulators of Postoperative Clot Firmness in a Surgical Intensive Care Unit.

Authors:  Sarah von Rappard; Corina Hinnen; Roger Lussmann; Manuela Rechsteiner; Wolfgang Korte
Journal:  Transfus Med Hemother       Date:  2017-03-22       Impact factor: 3.747

5.  Thrombin generation and fibrin clot formation under hypothermic conditions: an in vitro evaluation of tissue factor initiated whole blood coagulation.

Authors:  Matthew F Whelihan; Armin Kiankhooy; Kathleen E Brummel-Ziedins
Journal:  J Crit Care       Date:  2013-10-29       Impact factor: 3.425

6.  Management of Dilutional Coagulopathy during Pediatric Major Surgery.

Authors:  Thorsten Haas; Jacqueline Mauch; Markus Weiss; Markus Schmugge
Journal:  Transfus Med Hemother       Date:  2012-03-08       Impact factor: 3.747

7.  Discordant fibrin formation in hemophilia.

Authors:  K E Brummel-Ziedins; R F Branda; S Butenas; K G Mann
Journal:  J Thromb Haemost       Date:  2009-01-28       Impact factor: 5.824

Review 8.  Current management of massive hemorrhage in trauma.

Authors:  Pär I Johansson; Jakob Stensballe; Sisse R Ostrowski
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2012-07-09       Impact factor: 2.953

9.  Interventional Algorithms for the Control of Coagulopathic Bleeding in Surgical, Trauma, and Postpartum Settings: Recommendations From the Share Network Group.

Authors:  Manuela Carvalho; Anabela Rodrigues; Manuela Gomes; Alexandre Carrilho; António Robalo Nunes; Rosário Orfão; Ângela Alves; José Aguiar; Manuel Campos
Journal:  Clin Appl Thromb Hemost       Date:  2014-11-25       Impact factor: 2.389

Review 10.  Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?

Authors:  Wolfgang Korte
Journal:  J Blood Med       Date:  2014-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.